First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report

JCO Precis Oncol. 2024 Apr:8:e2300633. doi: 10.1200/PO.23.00633.

Authors

Camilla O Hoff¹, Eduardo Andreazza Dal Lago², Juliana Mota Siqueira¹, Luana G de Sousa¹, Adel K El-Naggar³, Jordi Rodon Ahnert⁴, Renata Ferrarotto¹

Affiliations

¹ Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX.
³ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
⁴ Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Abstract

First use of AXL-targeting in adenoid cystic carcinoma (ACC); with positive results, ACC now included in AXL studies.

Publication types

Case Reports

MeSH terms

Axl Receptor Tyrosine Kinase* / antagonists & inhibitors
Axl Receptor Tyrosine Kinase* / drug effects
Carcinoma, Adenoid Cystic* / drug therapy
Humans

Substances

AXL protein, human
Axl Receptor Tyrosine Kinase

Grants and funding

R03 DE031333/DE/NIDCR NIH HHS/United States